The discussion on NSCLC emphasizes the analysis of biomarkers such as CYFRA21-1, AGR2, CEA, PD-L1, CD9, CD63, CD81, Upar, GzmB, pro-SFTPB, and AFP. This evidence concerns the gene AGR2 and non-small cell lung carcinoma.